Cancer

Cancer

Cancer

Related Products

Cancer therapy has always been the focus of biomedical research and practice across the world. Cancer is a disease in which mutations or genomic changes enable cells to achieve a wide range of abilities in order to escape apoptosis and growth inhibition signals, resulting in unlimited cells growth and spread to other parts of the body. It is characterized by uncontrolled proliferation of abnormal cells and abnormal recognition of the immune system. There are different treatments for cancer, depending on its progress, the type of cancer, the types of treatments available, and the target of treatment. Surgery, chemotherapy (CT) and radiotherapy (RT) are the three main methods to treat cancer in the traditional way. However, these treatments are potentially toxic and may cause side effects and multidrug resistance. Although cancer therapy can prolong the life of patients, yet a large number of patients still die because of cancer recurrence, hence the research on cancer recurrence and metastasis has always been the focus in the field of clinical medicine. According to different nature of therapies, the types of cancer treatment can be divided into the following categories.

Cancer Related Products (22886):

Cat. No.	Product Name	CAS No.	Purity	Chemical Structure

MG-132	133407-82-6
MG-132 (Z-Leu-Leu-Leu-al) is a potent proteasome and calpain inhibitor with IC₅₀s of 100 nM and 1.2 μM, respectively. MG-132 effectively blocks the proteolytic activity of the 26S proteasome complex. MG-132, a peptide aldehyde, also is an autophagy activator. MG-132 also induces apoptosis^[1]^[2]^[3].

Rapamycin	53123-88-9
Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1^[1]. Rapamycin is an autophagy activator, an immunosuppressant^[2].

Ferrostatin-1	347174-05-4	99.96%
Ferrostatin-1 (Fer-1), a potent and selective ferroptosis inhibitor, suppresses Erastin-induced ferroptosis in HT-1080 cells (EC₅₀=60 nM). Ferrostatin-1, a synthetic antioxidant, acts via a reductive mechanism to prevent damage to membrane lipids and thereby inhibits cell death. Antifungal Activity^[1]^[2]^[3].

3-Methyladenine	5142-23-4
3-Methyladenine (3-MA) is a PI3K inhibitor. 3-Methyladenine is a widely used inhibitor of autophagy via its inhibitory effect on class III PI3K^[1].

Erastin	571203-78-6
Erastin is a ferroptosis inducer. Erastin shows selective cytotoxicity, targeting cells expressing oncogenic mutants of RAS. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity^[1]^[2]^[3].

Cisplatin	15663-27-1
Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy^[1]^[2]^[3].

Chloroquine	54-05-7	99.98%
Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM)^[1]^[2]^[3]^[4].

Bafilomycin A1	88899-55-2
Bafilomycin A1 (BafA1) is a specific and reversible inhibitor of vacuolar H⁺-ATPase (V-ATPase) with IC₅₀ values of 4-400 nmol/mg. Bafilomycin A1, a macrolide antibiotic, is also used as an autophagy inhibitor at the late stage. Bafilomycin A1 blocks autophagosome-lysosome fusion and inhibits acidification and protein degradation in lysosomes of cultured cells. Bafilomycin A1 induces apoptosis^[1]^[2]^[3].

RSL3	1219810-16-8	99.90%
RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells^[1].

Doxorubicin hydrochloride	25316-40-9
Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy^[1]^[2]^[3].

LY294002	154447-36-6
LY294002 is a broad-spectrum inhibitor of PI3K with IC₅₀s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively^[1]. LY294002 also inhibits CK2 with an IC₅₀ of 98 nM^[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC₅₀ of 1.4 μM. LY294002 is an apoptosis activator^[3].

Olaparib	763113-22-0	99.98%
Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC₅₀s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator^[1]^[2]^[3]^[4].

Y-27632 dihydrochloride	129830-38-2
Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor (ROCK-I K_i=220 nM; ROCK-II K_i=300 nM). Y-27632 dihydrochloride shows antiepileptic effects^[1]^[2]^[3]^[4].

Paclitaxel	33069-62-4	99.97%
Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy^[1]^[2].

Tamoxifen	10540-29-1	99.92%
Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells^[1]^[2]^[3]. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 µM and 1.8 µM, respectively^[5]. Tamoxifen activates autophagy and induces apoptosis^[4]. Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse^[6].

Z-VAD-FMK	161401-82-7
Z-VAD-FMK (Z-VAD(OH)-FMK) is a well-know pan caspase inhibitor, which does not inhibit ubiquitin carboxy-terminal hydrolase L1 (UCHL1) activity even at concentrations as high as 440 μM^[1].

Laduviglusib	252917-06-9
Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy^[1]^[2]^[3].

Acetylcysteine	616-91-1
Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor^[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases^[5]. Acetylcysteine induces cell apoptosis^[2]^[3]. Acetylcysteine also has anti-influenza virus activities^[7].

Venetoclax	1257044-40-8
Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a K_i of less than 0.01 nM. Venetoclax induces autophagy^[1]^[2]^[3].

Dexamethasone	50-02-2	99.86%
Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.